The focus of my team is on cognition and how it is affected by neuropsychiatric ailments, such as depression. We study maladaptation of synapses and circuitry brought about by unique molecular signatures in hippocampus and prefrontal cortex.
Our goal is to understand the specific molecular, cellular and network adaptations that occur in the brain in the earliest stages of Alzheimer’s diseasse, and to test how these adaptations can be used for early disease diagnosis and intervention.
Our research aims to discover new glial-based mechanisms of information processing in the brain in health and disease, with a focus on the role of astrocytes in the regulation of myelin and synaptic plasticity.
My Neuroproteomics team aims to (1) describe the protein complex nano-machinery that underlies synapse function and plasticity, and (2) reveal the alteration of synapse/tissue proteomes in cases of neuro-degenerative and neuropsychiatric disorders. Mass spectrometry based quantitative proteomics analysis is the leading technology behind these studies.
My aim is to unravel the neurobiological mechanisms underlying drug addiction with a particular focus on relapse mechanisms related to alcohol and nicotine. These studies have a strong multidisciplinary character and include behavioural analysis, proteomics, neurophysiology and opto- and chemogenetic approaches.
The overall objective of the Laboratory for Neuroregeneration is to unravel the biological mechanisms that govern successful regeneration in the PNS and that underlie degeneration and regenerative failure in the CNS. The primary long-term research objective is to make significant contributions to the field of restorative neuroscience and neurology.